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Immune dysfunction, a well-established feature of neuroinflammatory disease, is increasingly recognized in
neurodegenerative conditions. Its role is emerging as an early and active participant in neuropathology.
Inflammation could be modified, with disease-slowing effects, by targeted interventions; it is also readily
detectible and could serve as a source of valuable biomarkers.It is hardly controversial to assert
that abnormal inflammation can cause
damage to the central nervous system.
In multiple sclerosis (MS), the quintessen-
tial CNS inflammatory disorder, an adap-
tive immune response of obscure origin,
comprising antigen-specific T and B cells,
drives acute inflammatory events. Later,
an innate immune response (monocytes
and microglia) culminates, in progressive
cases, in a disease phase that may be
more neurodegenerative than inflamma-
tory. The inflammatory component of
MS is now well-known to be amenable
to modification by interventions target-
ing the immune system, from broad-
spectrum agents such as steroids and
interferons to more targeted agents
like monoclonal antibodies to individual
immune system components. Recently,
many have argued that early, aggressive
treatment of abnormal immune activity
during a key ‘‘window of opportunity’’
may be essential if the neurodegenerative
phase of the illness—and its inevitable
accumulation of disability—is to be pre-
vented.
Diseases like Alzheimer’s (AD), Parkin-
son’s (PD), Huntington’s (HD), and amy-
otrophic lateral sclerosis (ALS) have
traditionally been viewed as neurodegen-
erative, and with good reason: it is
primarily the death and dysfunction of
neurons that causes disability. But
increasingly, activation of various compo-
nents of the innate immune system is
recognized as a feature of these ‘‘neuro-
degenerative’’ diseases. If the immune
system is playing any active role in aneurodegenerative disease, for better or
for worse, then modifying it—enhancing
favorable behaviors or suppressing harm-
ful ones—may be capable of slowing
the progression of the disease. Even
if the immune system cannot be mani-
pulated to therapeutic effect, immune
derangements could perhaps be har-
nessed asmarkers of diagnosis or disease
progression.
The peripheral effectors of innate immu-
nity aremyeloid-derived bloodmonocytes
that additionally give rise to phagocytic
tissue macrophages, and to inflammatory
dendritic cells (DC). Conversely, brain
microglia (the macrophage/DC of the
CNS) are self-renewing and arise from
fetal myeloid progenitors. Microglial ‘‘acti-
vation’’ is now held to be more complex
than an all-or-nothing process. Depend-
ing on the stimulus and biochemical
milieu, a wide range of qualitatively
varied responses—pro- and anti-inflam-
matory, neuroprotective or neurotoxic—
may be elicited. Moreover, microglia
experiencing sustained stimulation enter
a state of chronic activation in which
toxic factors are continuously released,
with resulting ongoing damage to sur-
rounding tissue (reviewed in Ransohoff
and Perry, 2009).
Microglial activation can be identified
histologically and is both widespread
and concentrated on areas of pathology
in the brains of patients with AD, HD,
PD, and ALS (reviewed in Lobsiger and
Cleveland, 2007; Ransohoff and Perry,
2009; Schwab and McGeer, 2008). In
AD, activated microglia are seen toNeuron 6surround and infiltrate extracellular amy-
loid beta (Ab) plaques, while prevention
of macrophage and monocyte migration
and accumulation results in accelerated
pathology. Ab activates microglia into a
proinflammatory state, while simulta-
neously reducing their phagocytic ability.
Overall, while it is clear that microglia are
involved in the pathogenesis of AD, it is
far from apparent whether their overall
role in AD is neuroprotective, pathogenic,
or, most likely, a combination of both
(Schwab and McGeer, 2008). However,
long-term anti-inflammatory drug treat-
ment does appear to reduce susceptibility
to AD and PD, and immunomodulatory
therapies are currently a major area in
neurodegenerative research (Schwab
and McGeer, 2008; Hirsch and Hunot,
2009).
Microglial activation appears to be
a general response to extracellular fibrillar
protein, as it can also be triggered by
tau and a-synuclein. Extracellular a-synu-
clein aggregates, for instance, induce
microglial activation and release of proin-
flammatory cytokines, leading to dopami-
nergic neurodegeneration in PD (Hirsch
and Hunot, 2009). In ALS, activated
microglia overexpressing mutant SOD1
(mSOD1) can be seen to contribute to
neuronal death, and reducing mSOD1
levels in microglia has been seen to slow
disease progression significantly (Boille´e
et al., 2006). Progression of ALS probably
involves the action of abnormal protein
within cell types other than motor
neurons, which raises the possibility of
targeting nonneuronal cells both for4, October 15, 2009 ª2009 Elsevier Inc. 21
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(Lobsiger and Cleveland, 2007).
As a penetrant, monogenic condi-
tion, HD offers unique insights into
immune contributions to neurodegenera-
tion before disease onset. The mutant
huntingtin (mHtt) protein is expressed
ubiquitously, meaning that the function
of neurons, glial cells, and peripheral
immune cells may be altered by the muta-
tion. We demonstrated that monocytes/
macrophages and microglia are hyperac-
tive in HD, and overexpression of IL-6
and other proinflammatory cytokines can
be seen in postmortem HD striatum
(Bjo¨rkqvist et al., 2008). Since microglial
activation is known to occur in HD, these
findings suggest that not only domicroglia
in HD find themselves in an abnormal,
proinflammatory environment, but they
may also respond to this environment
maladaptively by potentially detrimental
overreaction, due to a direct effect of the
mutant htt protein within the microglia
(Bjo¨rkqvist et al., 2008). Indeed, a yeast
genomic screen revealed the microglial-
specific kynurenine monooxygenase
(KMO) pathway to be a highly significant
disease modifier in HD (Giorgini et al.,
2005), andwork is nowunderway to inves-
tigate whether downregulation of micro-
glia or the KMO pathway can alter the
natural history of HD.
Clearly an increased understanding of
innate immunity appears essential for
understanding some neurodegenerative
disease pathology. Microglial and innate
immune dysfunction may provoke CNS
pathogenesis and provide key clinical
targets years before disease onset. Alter-
natively, immune hyperactivity may reflect
some of the earliest detectable patholog-
ical events, and this may be detectable
before disease onset. Therefore, a key
question is whether CNS inflammatory
activity can be measured in vivo and
used for diagnostic purposes as potential
biomarkers of progression and/or to
measure the efficacy of possible treat-
ments.
The biochemical hallmarks of inflam-
matory activation, such as increased
levels of cytokines and chemokines in
the brain, can be detected readily post-
mortem and in animal models but
cannot be directly quantified in vivo in
patients. Positron-emission tomography
(PET) imaging using the radioligand 11C-22 Neuron 64, October 15, 2009 ª2009 Else(R)-PK11195, which binds the peripheral
benzodiazepine-binding site, enables the
visualization and quantification of micro-
glial activation in vivo. Using this tech-
nique, early microglial activation has
been shown in numerous neurodegenera-
tive diseases. In HD, microglial activation
can be detected in gene carriers many
years prior to disease onset (Tai et al.,
2007). Microglial activation can also be
detected in patients with mild cognitive
impairment (MCI) prior to progression to
AD (Fiala and Veerhuis, 2009), further
supporting the notion that an innate
immune response is an early event in
AD, and likewise supporting the impor-
tanceofmicroglial activation asapotential
biomarker. PET imaging, though expen-
sive and technically challenging, offers
one way in which CNS inflammation
could be monitored relatively directly as
a possible biomarker of neuropathology
or response to treatments. However,
11C-(R)-PK11195 cannot readily distin-
guish between qualitatively different
states of microglial activation, so cannot
discriminate between helpful and harmful
inflammatory activation. Numerous alter-
native PET ligands that may enable
in vivo imaging of other aspects of CNS
inflammation are under investigation.
Neuroinflammatory processes in neu-
rodegeneration can also be followed in
cerebrospinal fluid (CSF). This has been
suggested for PD where an increase
in proinflammatory cytokines can be
seen in CSF (Hirsch and Hunot, 2009).
Likewise, the proinflammatory cytokine
TNF-a has been found to be increased in
CSF in individuals with MCI who later
progress to AD (Fiala and Veerhuis,
2009). Our work in HD suggests there
may be parallel derangements of CNS
and peripheral inflammatory function
that translates into parallel changes in
CSF and plasma (Bjo¨rkqvist et al., 2008).
However, CSF levels of most cytokines
are unlikely to be useful alone to diagnose
or to differentiate different neurode-
generative diseases; instead, CSF inflam-
matory markers may be a useful tool
to monitor anti-inflammatory therapeutic
effects.
In MS, plasma immune measures
have been shown to be associated with
disease activity and MRI activity. How-
ever, the neuroinflammation of MS is
often striking, widespread, and sustained.vier Inc.Could inflammatory changes detectable
in blood inform us about the patho-
genesis of primarily neurodegenerative
diseases?
Our work in HD suggests that theremay
be parallel derangements of CNS and
peripheral inflammatory function. We
found a proinflammatory pattern of
cytokine elevation in plasma in HD, with
IL-6 significantly elevated in a group of
subjects predicted to be, on average,
16 years from the onset of disease signs.
Other cytokines including IL-8 and TNF- a
were elevated in patients with manifest
disease. These changes mirrored the
cytokine expression changes seen post-
mortem in HD striatum. Further experi-
ments using LPS stimulation of mono-
cytes from premanifest HD mutation
carriers revealed hyperactivity similar to
that seen in HD microglia, arguing in favor
of a cell-autonomous effect of mutant
huntingtin in peripheral myeloid cells as
well as in the CNS. The nature of the
interplay between CNS and peripheral
inflammatory derangement is unclear,
but the passage of inflammatory mole-
cules across the blood-brain barrier, in
either direction, with possible effects on
the neurodegenerative process, cannot
be excluded. Further work exploring the
interplay between central and peripheral
inflammatory derangement is essential
in determining the ability of peripheral
innate immune phenotypes to shed light
on CNS neurodegeneration (Bjo¨rkqvist
et al., 2008). This is also true of the other
neurodegenerative diseases, where the
balance of primary and secondary abnor-
malities of the peripheral immune system
has been little studied, but is becoming
of increasing interest.
Many studies in AD have reported alter-
ations in systemic immune responses
involving both innate and humoral
immune systems, including changes in
lymphocyte and macrophage distribution
and activation, the presence of autoanti-
bodies, complement system alterations,
and abnormal cytokine production in
cerebrospinal fluid (CSF) and plasma
(reviewed in Lucin and Wyss-Coray,
2009 [this issue of Neuron]). Increasing
evidence from studies in animal models
of AD shows that peripheral immune
cells infiltrate the brain and may modulate
the disease. This work opens up possi-
ble new therapeutic avenues in AD
Neuron
NeuroViewthrough modulation of peripheral immune
function.
The study of the role of microglia in
neurodegeneration is limited in part by
the inaccessibility of human microglia
in vivo. Monocytes and macrophages,
as the peripheral immune cell equivalents
of central microglia, are easily accessi-
ble and may conceivably provide model
systems of similar pathological pro-
cesses occurring in CNS microglia.
Experimental assessments of sponta-
neous and stimulated production of
cytokines and chemokines and their
receptors in patients with neurodegenera-
tive diseases has been of increasing
interest, with cytokine release from blood
mononuclear cells in response to stimula-
tion correlating with disease severity in AD
(Lucin and Wyss-Coray, 2009). Investi-
gating transcriptional dysregulation in
peripheral monocytes in response to
stimulation using expression profiling
could identify genes specifically dysregu-
lated in disease and may identify gene
networks and cellular pathways important
for disease pathogenesis and help iden-
tify new potential targets for therapeutic
intervention.
Study of the peripheral innate immune
system may also be relevant to disease
symptomatology itself. Weight loss and
muscle wasting are commonly found
in patients with these disorders, and
interestingly there is a potential impact
of immune alteration on these aspects
of the peripheral phenotype. Similar,
depression is a common feature in neuro-
degenerative diseases, and again there
is a potential link to innate immune
dysfunction. Therefore, study of periph-
eral cytokines, chemokines, complement
factors, and signaling proteins may pro-
vide an accessible source of biomarkers
useful in diagnosing neurodegenerative
diseases, predicting progression and
phenotype, or monitoring therapeutic
interventions.
The availability of reliable tests on
accessible tissues such as blood would
be a valuable asset. As a key modulator
of the complement cascade and impli-
cated in neuroinflammation, clusterin
was previously shown to be upregulated
in peripheral blood in HD (Dalrymple
et al., 2007). Recently, large genome-
wide association studies have also identi-
fied variants in the clusterin gene (CLUS)to be associated with an increased risk
of sporadic AD (Harold et al., 2009). Clus-
terin and related proteins have now been
implicated in the neuropathogenesis of
MS, AD, PD, and AD. Evidently, peripheral
inflammatory alterations have the power
not only to offer potential biomarkers but
also to highlight salient foci of pathogenic
significance.
Eighteen proteins in plasma (among
them, several proteins involved in the
immune response) were also recently
shown to classify blinded samples from
AD and control subjects with close to
90% accuracy and to identify patients
who had mild cognitive impairment that
progressed to Alzheimer’s disease
(Ray et al. 2007). Ongoing inflammatory
processes can provide a characteristic
profile of immune markers in plasma,
creating optimism for finding a detectable
disease-specific pattern of changes. In
PD, an inflammatory process can also
be detected in serum, and high plasma
concentrations of IL-6 may predict an
increased risk of developing PD (reviewed
in Hirsch and Hunot, 2009). In ALS,
immune markers can be seen to follow
disease progression (reviewed in Turner
et al., 2009).
There are, however, strong caveats to
the use of plasma cytokines alone as
biomarkers of disease progression or
diagnostic predictors. It is known that
cytokines display diurnal variation and
that this can alter with disease. Such
disease-related differences make stan-
dardization of sampling time challeng-
ing. Needless to say, levels of many
immune molecules are greatly altered
by infection and concomitant inflamma-
tory illness. Other factors likely to influ-
ence cytokine levels include immuno-
modulatory actions of cortisol, body
mass index, visceral fat deposits, smok-
ing status, exercise, diet, dietary supple-
mentation (especially fatty acids), and
medications, adding to the challenge of
developing immune markers specific for
disease. Also, neurodegenerative disor-
ders are often slowly progressive, and
changes are likely to be subtle and diffi-
cult to monitor. More likely perhaps,
monocyte function assays or distinct
patterns and profiles of changes (Ray
et al., 2007) might prove to be useful
in following disease progression or as
pharmacodynamic biomarkers.Neuron 6Demonstrating an association between
inflammatory markers and neurodegener-
ative disorders is a necessary first step,
but such studies do not themselves
establish the full clinical utility of a
biomarker. Multicenter longitudinal cohort
analysis of candidate markers and trials in
which clinical endpoints, possible treat-
ments, and potential biomarkers are
studied will be essential in the validation
process.
The prospect of immunomodulatory
treatments has further ramifications for
the development of inflammatory bio-
markers, because such therapies would
be expected to influence the marker
directly. This does not mean that inflam-
matory markers and treatments are mutu-
ally exclusive, but that in the context of
such treatments, immune molecules
may be pharmacodynamic markers of
target occupancy, rather than surrogates
for clinical endpoints.
Nonetheless, there is room for opti-
mism that with a better understanding
of the innate immune system and its
interplay with the CNS in health and
disease, and through combining bio-
marker information from different sour-
ces, immune activation could serve as
a valuable window into the otherwise
hidden CNS milieu.
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